Zachary Roberts Biography and Net Worth

Executive Vice President, Research & Development, Chief Medical Officer of Allogene Therapeutics

Zachary (Zach) Roberts, M.D., Ph.D., is the Executive Vice President, Research & Development, and Chief Medical Officer of Allogene. Zach is a trained immunologist and board-certified oncologist with extensive experience in clinical oncology, including the development of cell therapies. Before joining Allogene, Zach was Chief Medical Officer of Instil Bio, where he led development of both clinical and pre-clinical programs. Prior to that, Dr. Roberts held various roles of increasing responsibility at Kite Pharma (acquired by Gilead in 2017), where he was instrumental in the development and execution of the ZUMA trials across multiple indications for YESCARTA®, the first autologous CAR T therapy approved for non-Hodgkin lymphoma. Before joining Kite, Zach led several solid tumor studies at Amgen. He holds an M.D. and Ph.D. in immunology from the University of Maryland, Baltimore and completed clinical and post-graduate training at Massachusetts General Hospital and the Dana-Farber Cancer Institute.

What is Zachary Roberts' net worth?: The estimated net worth of Zachary Roberts is at least $702.80 thousand as of January 21st, 2025. Dr. Roberts owns 488,054 shares of Allogene Therapeutics stock worth more than $702,798 as of December 4th. This net worth evaluation does not reflect any other investments that Dr. Roberts may own. Additionally, Dr. Roberts receives an annual salary of $747,390.00 as Executive Vice President, Research & Development, Chief Medical Officer at Allogene Therapeutics. Learn More about Zachary Roberts' net worth.
How old is Zachary Roberts?: Dr. Roberts is currently 46 years old. There are 8 older executives and no younger executives at Allogene Therapeutics. The oldest executive at Allogene Therapeutics is Dr. Arie S. Belldegrun F.A.C.S., M.D., Co-Founder & Executive Chairman, who is 75 years old. Learn More on Zachary Roberts' age.
What is Zachary Roberts' salary?: As the Executive Vice President, Research & Development, Chief Medical Officer of Allogene Therapeutics, Inc., Dr. Roberts earns $747,390.00 per year. The highest earning executive at Allogene Therapeutics is Dr. David D. Chang M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $994,600.00 per year. Learn More on Zachary Roberts' salary.
How do I contact Zachary Roberts?: The corporate mailing address for Dr. Roberts and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Zachary Roberts' contact information.
Has Zachary Roberts been buying or selling shares of Allogene Therapeutics?: Zachary Roberts has not been actively trading shares of Allogene Therapeutics over the course of the past ninety days. Most recently, Zachary Roberts sold 27,199 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a transaction totalling $48,414.22. Following the completion of the sale, the executive vice president now directly owns 488,054 shares of the company's stock, valued at $868,736.12. Learn More on Zachary Roberts' trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), David Chang (President, Chief Executive Officer and Co-Founder), Earl Douglas (SVP), Franz Humer (Director), Stephen Mayo (Director), Geoffrey Parker (Executive Vice President, Chief Financial Officer), Zachary Roberts (Executive Vice President, Research & Development, Chief Medical Officer), Owen Witte (Director), and Annie Yoshiyama (SVP). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, insiders at the sold shares 10 times. They sold a total of 169,568 shares worth more than $294,129.46. The most recent insider tranaction occured on October, 21st when CFO Geoffrey M Parker sold 36,744 shares worth more than $46,297.44. Insiders at Allogene Therapeutics own 13.2% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 10/21/2025.

Zachary Roberts Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/21/2025	Sell	27,199	$1.78	$48,414.22	488,054

Zachary Roberts Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.44

$1.41

$1.51

50 Day Range

MA: $1.28

$1.05

$1.52

2 Week Range

Now: $1.44

$0.86

$3.78

Volume

1,536,230 shs

Average Volume

2,359,507 shs

Market Capitalization

$323.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Zachary Roberts Biography and Net Worth

What is Zachary Roberts' net worth?

How old is Zachary Roberts?

What is Zachary Roberts' salary?

How do I contact Zachary Roberts?

Has Zachary Roberts been buying or selling shares of Allogene Therapeutics?

Who are Allogene Therapeutics' active insiders?

Are insiders buying or selling shares of Allogene Therapeutics?